Navigation Links
Generex Subsidiary Antigen Express Available for Partnering & Collaboration Meetings at the 2012 JPMorgan Healthcare Conference
Date:1/4/2012

WORCESTER, Mass. and TORONTO, Jan. 4, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) announced today that representatives of the Company's wholly-owned subsidiary, Antigen Express, Inc., will be in attendance at the 2012 JPMorgan Healthcare Conference in San Francisco from January 8 through 13.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )

Representatives of Antigen Express will be available over the course of the conference to meet with prospective partners, collaborators, and investors in respect of the Antigen Express proprietary platform immunotherapeutic vaccine technologies.

Mark Fletcher, Generex President & Chief Executive Officer, has commented:  "In particular, the recently announced positive interim clinical data from our Phase 2b study in HER-2 expressing breast cancer subjects makes the time ripe for discussions with prospective partners and collaborations in respect of a Phase 3 study of the breast cancer vaccine."

Interested parties are invited to contact:

Mr. Joseph Moscato
Seahawk Capital Partners, Inc.
646-599-6222
jmoscato@seahawkcap.com

About AE37 and Ii-Key Hybrid Platform Technology

Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs.  The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells.  Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.

The first product candidate utilizing the Company's novel Ii-Key Hybrid technology platform is a HER-2/neu Peptide Vaccine (AE37).  This "off-the-shelf" cancer immunotherapy product candidate is easier and less costly to produce than comparable cell-based approaches.  AE37 is derived from a peptide fragment of the human epidermal growth factor receptor 2 (HER2) oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian and other cancers.  AE37 represents the only HER2-based peptide vaccine currently being studied in a randomized trial and its use is not restricted to patients with a particular type of human leukocyte antigen (HLA) peptide.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


'/>"/>
SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
2. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
3. Generex Announces Presentations of Novel Vaccine Strategies
4. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
5. Generex Announces Sales Agreement with Elias Shaker & Company
6. Generex Presents Abstract at EASD Annual Meeting
7. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
8. Generex Biotechnology Provides a Corporate Update to Address Managements Strategic Initiatives for Growth
9. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
10. Generex Provides Clarification for Special Meeting Voting
11. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 Today Stock-Callers.com ... stocks, which are: Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: ... (NASDAQ: SSH ). These companies are part of ... gains on Thursday, March 23 rd , 2017, with the ... shares of health care companies in the S&P 500 were ...
(Date:3/24/2017)... March 23, 2017  HealthMine surveys with 9,250 insured ... that health plan members want help from their plans ... engaged in their health, 2) help closing gaps in ... for health and 5) relevant, real-time guidance. Meeting these ... healthcare costs. A Reason to ...
(Date:3/24/2017)... -- The Board of Directors of Nordic Nanovector ... including the complete 2016 Annual Accounts with notes. The report ... website in the section Investor Relations/Reports and presentations/Annual Reports. ... For further ... Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
Breaking Medicine Technology:
(Date:3/24/2017)... New York, NY (PRWEB) , ... March 24, ... ... a global scale; from third world countries to hospitals in the United States, ... sparks a conversation on the current obstacles facing infection prevention and offers strategies ...
(Date:3/24/2017)... ... 2017 , ... The iaedp Foundation, the premier provider of educational programs and ... from the full spectrum of disordered eating, announced today that the 2017 Symposium set ... 50 states and several countries converged on the Green Valley Resort in Las Vegas. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Northridge ... now offering treatments for sleep apnea and TMJ at their office. TMJ, or ... , specifically the obstructive type, is increasingly being treated at dental offices with ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower ... upgrading their training and leads programs. , In February, 2017, Empower Brokerage introduced ... agents, Performance Partners is designed to teach how to maximize their sales efforts, ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of Saints: ... of God in congregations across the United States. “The Communion of Saints” ... 1964 who has served congregations in seven states throughout his long career of ...
Breaking Medicine News(10 mins):